Repligen (NASDAQ:RGEN) Now Covered by Wolfe Research

Wolfe Research began coverage on shares of Repligen (NASDAQ:RGEN) in a report released on Thursday morning, MarketBeat.com reports. The firm issued a peer perform rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on RGEN. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Finally, Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Down 11.8 %

NASDAQ RGEN traded down $16.79 during trading hours on Thursday, hitting $125.64. The company had a trading volume of 466,512 shares, compared to its average volume of 659,362. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a market capitalization of $7.04 billion, a price-to-earnings ratio of -361.50, a P/E/G ratio of 4.36 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm’s 50 day moving average is $141.59 and its 200 day moving average is $144.78.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the firm earned $0.23 EPS. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. Sell-side analysts anticipate that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank increased its stake in shares of Repligen by 1.5% during the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 75 shares during the period. DekaBank Deutsche Girozentrale grew its position in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after buying an additional 89 shares during the last quarter. Ballentine Partners LLC grew its position in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after buying an additional 105 shares during the last quarter. Diversified Trust Co grew its position in Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after buying an additional 106 shares during the last quarter. Finally, CWM LLC grew its position in Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock worth $64,000 after buying an additional 114 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.